Anti-Interferon gamma Anticorpo [P2C11] (Biotin) (A269721)

The objective of this study was to determine the efficacy of a commercially available porcine reproductive and respiratory syndrome virus (PRRSV)-1 modified-live virus (MLV) vaccine against PRRSV-1 and PRRSV-2 challenge in late-term pregnancy gilts. Gilts were vaccinated with the PRRSV-1 MLV vaccine at 4 weeks prior to breeding and then challenged intranasally with PRRSV-1 or PRRSV-2 at 93 days of gestation. After PRRSV-1 challenge, vaccinated pregnant gilts had a significantly longer gestation period, significantly higher numbers of live-born and weaned piglets and a significantly lower number of stillborn piglets at birth compared to unvaccinated pregnant gilts. No significant improvement in reproductive performance was observed between vaccinated and unvaccinated pregnant gilts following PRRSV-2 challenge. Vaccinated pregnant gilts also exhibited a significantly improved reproductive performance after challenge with PRRSV-1 compared to vaccinated pregnant gilts following PRRSV-2 challenge. The PRRSV-1 MLV vaccine was able to reduce PRRSV-1 but not PRRSV-2 viremia in pregnant gilts. Vaccinated gilts also showed a significantly higher number of PRRSV-1-specific IFN-?-secreting cells (IFN-?-SC) compared to PRRSV-2-specific IFN-?-SC. The data presented here suggest that the vaccination of pregnant gilts with a PRRSV-1 MLV vaccine provides good protection against PRRSV-1 but only limited protection against PRRSV-2 challenge in late-term pregnancy gilts based on improvement of reproductive performance, reduction in viremia and induction of IFN-?-SC.

Classical swine fever is an economically important, highly contagious disease of swine worldwide. Subunit vaccines are a suitable alternative for the control of classical swine fever. However, such vaccines have as the main drawback the relatively long period of time required to induce a protective response, which hampers their use under outbreak conditions. In this work, a lentivirus-based gene delivery system is used to obtain a stable recombinant HEK 293 cell line for the expression of E2-CSFV antigen fused to porcine CD154 as immunostimulant molecule. The E2-CD154 chimeric protein was secreted into the medium by HEK293 cells in a concentration around 50mg/L in suspension culture conditions using spinner bottles. The E2-CD154 immunized animals were able to overcome the challenge with a high virulent CSF virus strain performed 7days after a unique dose of the vaccine without clinical manifestations of the disease. Specific anti-CSFV neutralizing antibodies and IFN-? were induced 8days after challenge equivalent to 14days post-vaccination. The present work constitutes the first report of a subunit vaccine able to confer complete protection by the end of the first week after a single vaccination. These results suggest that the E2-CD154 antigen could be potentially used under outbreak conditions to stop CSFV spread and for eradication programs in CSF enzootic areas.

To put a Respiratory Syncytial Virus (RSV) vaccine onto the market, new vaccination strategies combining scientific and technical innovations need to be explored. Such a vaccine would also need to be adapted to the vaccination of young children that are the principal victims of acute RSV infection. In the present project, we describe the development and the preclinical evaluation of an original epicutaneous RSV vaccine that combines two technologies: Viaskin® epicutaneous patches as a delivery platform and RSV N-nanorings (N) as a subunit antigen. Such a needle-free vaccine may have a better acceptability for the vaccination of sensible population such as infants since it does not require any skin preparation. Moreover, this self-applicative vaccine would overcome some issues associated to injectable vaccines such as the requirement of sterile medical devices, the need of skilled health-care professionals and the necessity of stringent store conditions. Here, we demonstrate that Viaskin® patches loaded with a formulation containing N-nanorings (Viaskin®-N) are highly immunogenic in mice and promotes a Th1/Th17 oriented immune response. More importantly, Viaskin®-N epicutaneous vaccine confers a high level of protection against viral replication upon RSV challenge in mice, without exacerbating clinical symptoms. In swine, which provides the best experimental model for the transcutaneous passage of drug/antigen in human skin, we have shown that GFP fluorescent N-nanorings, delivered epicutaneously with Viaskin® patches, are taken up by epidermal Langerhans cells. We have also demonstrated that Viaskin®-N induced a significant RSV N-specific T-cell response in pig. In conclusion, Viaskin®-N epicutaneous vaccine seems efficient to protect against RSV infection in animal model.

?d T cells are highly abundant in the blood and spleen of pigs but little is known about their functional differentiation. In this study the potential of the type-1 polarizing cytokines IL-12 and IL-18 in combination with IL-2 and Concanavalin A (ConA) to stimulate porcine ?d T cells was investigated. Stimulation of purified ?d T cells with ConA and IL-2 induced a strong proliferation of CD2(-) ?d T cells, whereas additional stimulation with IL-12 and IL-18 caused a stronger proliferation of CD2(+) ?d T cells. IFN-? could only be detected in supernatants of ?d T-cell cultures supplemented with IL-12 and IL-18. Experiments with sorted CD2/SWC5-defined ?d T-cell subsets revealed that CD2(+)SWC5(-) ?d T cells are the main producers of IFN-? following stimulation with IL-2/IL-12/IL-18. Additional stimulation with ConA led to an upregulation of CD2 within the CD2(-) ?d T cell subsets, indicating a previously unnoticed plasticity of CD2-defined ?d T cell subsets.

GALT induces tolerance to foreign food antigens and plays an important role in the development of food allergies and the inflammatory bowel disease. The immune function of GALT is significantly influenced by an equilibrium between Th1 and Th2 subpopulations and the cytokines they produce. Th1 cytokines participate in the induction of a cell-mediated immune response, whereas Th2 cytokines induce powerful antibody-mediated responses. Changes in Th1/Th2 cell polarization of an immune response are associated with susceptibility to autoimmune and infectious diseases. This experiment investigated changes in cytokine levels produced by Th1 and Th2 cells in ileal Payer's patches in gilts exposed to ZEN doses below the NOEL (approximately 8 microg kg(-1) BW) for 14, 28 and 42 days. A significant linear increase in IL-4 (40.32 +/- 1.55 ng mg(-1)--137.60 +/- 29.96 ng mg(-1)), and IL-10 (5.99 +/- 0.15 ng mg(-1)--16.39 +/- 1.11 ng mg(-1)) concentrations was observed. An increase in Th1 (IL-2 and IFN-gamma) cytokine levels was also noted in the experimental group, but it was not statistically significant. An HPLC analysis of Peyer's patches in group E animals revealed a linear increase in ZEN concentrations (3.65 +/- 0.91 ng g(-1)--4.72 +/- 1.85 ng g(-1)) and an absence of alpha-ZEL. IL-4 stimulates monocytes and macrophages, it induces the production of proinflammatory cytokines and it may directly and indirectly contribute to the development of inflammatory foci. Higher IL-4 levels could shift polarization toward Th2 cells, stimulate B cells to undergo class switching to produce IgE and contribute to the development of allergies.